基石藥業-B(02616.HK):將在第66屆美國血液學會(ASH)年會上公佈CS5001針對淋巴瘤的最新臨牀數據
格隆匯11月6日丨基石藥業-B(02616.HK)發佈公吿,公司將在第66屆美國血液學會(ASH)年會上公佈管線2.0重磅產品CS5001(ROR1 ADC)針對淋巴瘤的最新臨牀數據。ASH年會將於 2024年12月7日至12月10日在美國加利福尼亞州聖地亞哥及線上舉行。
CS5001是目前已知首個在實體瘤和淋巴瘤中均觀察到臨牀療效的ROR1 ADC。根據公司在2024年美國臨牀腫瘤學會(ASCO)年會上公佈其首次人體研究的初步數據,CS5001在不同劑量水平、對於多線經治的晚期實體瘤和淋巴瘤均能表現出良好的耐受性和令人鼓舞的抗腫瘤活性。
公司將在此次ASH年會公佈CS5001首次人體研究中針對晚期B-細胞淋巴瘤的最新安全性和有效性數據。摘要數據截止日時已經可以觀察到,CS5001在所有劑量水平、針對可評估的晚期B-細胞淋巴瘤患者的總體客觀緩解率(ORR)達到43.5%。從初始起效劑量起,CS5001針對晚期霍奇金淋巴瘤的ORR達60.0%,非霍奇金淋巴瘤的ORR達50.0%。繼摘要數據截止日之後,我們在初步選定的II期推薦劑量(RP2D)水平入組了更多淋巴瘤患者,更新的數據屆時將在 ASH年會壁報中詳細公佈。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.